What to expect after endometrial cancer treatment

Finishing treatment for endometrial (uterine) cancer is a significant milestone, but staying vigilant afterward matters just as much. Cancer recurrence is a real concern for many survivors, with most recurrences happening within the first three years after treatment ends. That’s why a structured monitoring plan isn’t optional. It’s a core part of your care.

Monitoring serves two critical purposes: catching any cancer recurrence signs as early as possible, and supporting your overall health and quality of life after treatment. Early detection gives you more options. 

What does monitoring actually look like in practice? The schedule, tests, and what to watch for can vary based on your cancer stage, treatment type, and individual risk factors. The next section breaks down the typical follow-up timeline you can expect.

What to expect: typical follow-up schedule

Progression monitoring after uterine (endometrial cancer) treatment follows a structured rhythm designed to catch any changes early. According to the American Cancer Society, a typical follow-up schedule for endometrial (uterine) cancer looks like this:

Evidence-based guidance powered by NCCN Guidelines®

Personalized treatment plans shaped by the latest oncology standards—tailored to your diagnosis.

Get started

View your personalized treatment plan in the Outcomes4Me app

Use your diagnosis to unlock personalized NCCN Guidelines®-aligned recommendations.

Continue in app

• Years 1–2: Appointments every 3–6 months
• Years 3–5: Visits every 6–12 months
• After year 5: Annual check-ups

Each visit generally includes a pelvic exam, a review of any new symptoms, and a conversation about your overall health. Every patient’s plan is different, and your care team will tailor the schedule based on your specific diagnosis and treatment. To see what this can look like in practice, a real-world scenario can make it more concrete.

Recognizing symptoms of recurrence

Knowing which symptoms to watch for enables you to act quickly rather than wait for your next scheduled check-in. Common warning signs of uterine (endometrial) cancer include:

• Unusual vaginal bleeding or discharge
• Pelvic pain or pressure
• Unexplained weight loss
• Persistent bloating or abdominal discomfort
• New pain in the back, legs, or hips

Any new or unusual symptom should be reported to your provider promptly. Don’t wait until your next appointment. It’s worth noting that some recurrences are detected before symptoms appear at all, which is precisely why scheduled monitoring remains essential.

Staying alert to physical changes — and feeling confident enough to speak up about them — is one of the most practical things you can do. 

How to monitor for endometrial (uterine) cancer recurrence

Post-treatment monitoring isn’t a single test or a one-size-fits-all protocol. It’s a structured, evolving process that your care team tailors to your specific situation. In practice, monitoring typically combines scheduled office visits, physical examinations, and symptom-based conversations rather than routine imaging for every patient.

During follow-up appointments, your provider will likely perform a pelvic exam to check for any physical signs of recurrence. Imaging tests and Pap smears may also be ordered if there are any concerns that arise.

Frequently asked questions about post-treatment monitoring

Endometrial cancer surveillance raises a lot of questions. Here are answers to some of the most common ones.

• How soon after treatment does monitoring begin? Typically, within the first few months. Most care teams schedule the first follow-up visit around 3 months post-treatment, then continue at regular intervals from there.
• What symptoms should prompt a call to your care team before a scheduled visit? Don’t wait for your next appointment if you notice unusual vaginal bleeding, pelvic pain, persistent bloating, unexplained weight loss, or shortness of breath. Reporting new or worsening symptoms promptly is one of the most reliable ways to catch recurrence early.
• Will imaging be part of every follow-up? Not necessarily. Routine scans aren’t standard for all patients. Your provider will weigh your individual risk profile when deciding whether imaging is warranted at a given visit.
• Does surveillance change over time? Yes. Appointments typically become less frequent as the years pass and no signs of recurrence emerge. The intensity of monitoring reflects where you are in the post-treatment timeline. Understanding those shifts — and what they mean for your care — sets the stage for the practical takeaways ahead.

Don’t miss the latest updates in endometrial (uterine) cancer care. Join Outcomes4Me to stay informed on emerging research.